David Jürgens

David Jürgens is a researcher affiliated with Ludwig Maximilian University of Munich (LMU Munich), working in the Department of Biochemistry. He has experience in both academic and industrial settings, including roles as a postdoc at LMU Munich (Oct 2024 - March 2025) and Chief Operating Officer (COO) at RNhale since April 2024. His academic journey includes completing a PhD in Pharmaceutical Sciences (2021-2024) and obtaining a Board License as a Pharmacist (2020).

• PhD in Pharmaceutical Sciences, LMU Munich (2021-2024)
• Board License as a Pharmacist (2020)
• Pharmacy School, LMU Munich (2015-2019)

His research focuses on nucleic acid delivery systems, particularly lipid nanoparticles (LNPs) and polymer-based carriers for therapeutic applications in respiratory diseases and cancer treatment. Key areas include siRNA formulation, endosomal escape optimization, and targeted delivery to immune cells.

Publications highlight his contributions to pulmonary drug delivery for allergic asthma, macrophage repolarization strategies for cancer, and advanced techniques for LNP manufacturing. He has collaborated extensively with Prof. Olivia M. Merkel's research group.

Current roles combine academic research (postdoc) with industrial leadership (COO), indicating interdisciplinary expertise bridging pharmaceutical sciences and biotechnology entrepreneurship.